Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies
BackgroundUmbralisib, a dual PI3Kδ/CK-1ϵ inhibitor, has shown clinical activity in various hematologic malignancies. However, a systematic assessment of its efficacy and safety is still lacking. This study provides a comprehensive evaluation based on current clinical evidence.MethodsA comprehensive...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-01-01
|
| Rangatū: | Frontiers in Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1591759/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|